Makker Gotham
CIK: 0001726391
Associated companies
Transaction History
| RCKT | ▲ Buy | Grant | 30,000 | $0 | 6/18/2025 | View on chart |
| RCKT | ▲ Buy | Grant | 19,434 | $0 | 6/18/2025 | View on chart |
| RCKT | ▼ Sell | Open Market | 274,000 | $7.8M | 3/21/2024 | View on chart |
| RCKT | ▼ Sell | Open Market | 20,000 | $451K | 11/15/2023 | View on chart |
| RCKT | ▼ Sell | Open Market | 4,677 | $99K | 9/29/2023 | View on chart |
| RCKT | ▼ Sell | Open Market | 10,312 | $217K | 9/28/2023 | View on chart |
| RCKT | ▼ Sell | Gift | 621,500 | $0 | 7/27/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Rocket Pharmaceuticals Gets FDA Alignment on Heart Drug Trial
Rocket Pharmaceuticals has secured FDA alignment on a trial for its heart drug, which may help address prior safety concerns. This regulatory step is significant for the company's development timeline. The stock is currently trading near its 52-week low, reflecting ongoing market caution despite this progress.
Rocket Pharmaceuticals Gets FDA Alignment on Heart Drug Trial. Rocket Pharmaceuticals has secured FDA alignment on a trial for its heart drug, which may help address prior safety concerns. This regulatory step is significant for the company's development timeline. The stock is currently trading near its 52-week low, reflecting ongoing market caution despite this progress.